239 related articles for article (PubMed ID: 29221181)
41. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
Chung CG; Poligone B
Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
[TBL] [Abstract][Full Text] [Related]
42. The utility of bexarotene in mycosis fungoides and Sézary syndrome.
Panchal MR; Scarisbrick JJ
Onco Targets Ther; 2015; 8():367-73. PubMed ID: 25678803
[TBL] [Abstract][Full Text] [Related]
43. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
44. Single-Cell Heterogeneity of Cutaneous T-Cell Lymphomas Revealed Using RNA-Seq Technologies.
Rassek K; Iżykowska K
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751918
[TBL] [Abstract][Full Text] [Related]
45. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
46. Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome.
Maredia H; Cozzio A; Dummer R; Ramelyte E; Kim EJ; Rozati S
JAAD Case Rep; 2021 Sep; 15():92-96. PubMed ID: 34458536
[No Abstract] [Full Text] [Related]
47. No evidence of HTLV-I proviral integration in lymphoproliferative disorders associated with cutaneous T-cell lymphoma.
Wood GS; Schaffer JM; Boni R; Dummer R; Burg G; Takeshita M; Kikuchi M
Am J Pathol; 1997 Feb; 150(2):667-73. PubMed ID: 9033279
[TBL] [Abstract][Full Text] [Related]
48. Primary cutaneous T-cell lymphoma: review and current concepts.
Siegel RS; Pandolfino T; Guitart J; Rosen S; Kuzel TM
J Clin Oncol; 2000 Aug; 18(15):2908-25. PubMed ID: 10920140
[TBL] [Abstract][Full Text] [Related]
49. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma.
Seto AG; Beatty X; Lynch JM; Hermreck M; Tetzlaff M; Duvic M; Jackson AL
Br J Haematol; 2018 Nov; 183(3):428-444. PubMed ID: 30125933
[TBL] [Abstract][Full Text] [Related]
50. Human Endogenous Retrovirus Expression in Primary Cutaneous T-Cell Lymphomas.
Fava P; Bergallo M; Astrua C; Brizio M; Galliano I; Montanari P; Tovo PA; Novelli M; Savoia P; Quaglino P; Fierro MT
Dermatology; 2016; 232(1):38-43. PubMed ID: 26580164
[TBL] [Abstract][Full Text] [Related]
51. The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities.
Patil K; Sher G; Kuttikrishnan S; Moton S; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
Semin Cell Dev Biol; 2024 Feb; 154(Pt C):239-249. PubMed ID: 36216715
[TBL] [Abstract][Full Text] [Related]
52. Mycosis fungoides/Sézary syndrome: report of an unusual case.
Mehta A; Dhungel BM; Khan MF
J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic tools in Sezary syndrome.
Möbs M; Knott M; Fritzen B; Pullmann S; Sterry W; Assaf C
G Ital Dermatol Venereol; 2010 Jun; 145(3):385-91. PubMed ID: 20461046
[TBL] [Abstract][Full Text] [Related]
54. Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients.
Dobos G; Pohrt A; Ram-Wolff C; Lebbé C; Bouaziz JD; Battistella M; Bagot M; de Masson A
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050643
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of treatments for mycosis fungoides and Sézary syndrome: nationwide survey responses.
Gettler SL; Fung MA
Dermatol Online J; 2005 Dec; 11(3):6. PubMed ID: 16409902
[TBL] [Abstract][Full Text] [Related]
56. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
[TBL] [Abstract][Full Text] [Related]
57. Distinctive phorbol ester-induced morphological and surface antigen changes in mycosis fungoides, the Sézary syndrome, and adult T-cell leukemia.
Kadin ME; Nasu K; Sako D; Su IJ
Cancer Res; 1984 Aug; 44(8):3383-7. PubMed ID: 6611200
[TBL] [Abstract][Full Text] [Related]
58. mAb14, a Monoclonal Antibody against Cell Surface PCNA: A Potential Tool for Sezary Syndrome Diagnosis and Targeted Immunotherapy.
Knaneh J; Hodak E; Fedida-Metula S; Edri A; Eren R; Yoffe Y; Amitay-Laish I; Prag Naveh H; Lubin I; Porgador A; Moyal L
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686697
[No Abstract] [Full Text] [Related]
59. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.
Zhang C; Ni X; Konopleva M; Andreeff M; Duvic M
J Invest Dermatol; 2004 Aug; 123(2):380-7. PubMed ID: 15245439
[TBL] [Abstract][Full Text] [Related]
60. Prevalence and severity of pruritus in cutaneous T cell lymphoma.
Vij A; Duvic M
Int J Dermatol; 2012 Aug; 51(8):930-4. PubMed ID: 22788808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
